BIONTECH SE SPON. ADRS 1
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Fabian Lorenz on August 24th, 2026 | 07:35 CEST
Share Price Surges and Buy Ratings: New Price Target for Almonty as CTS EVENTIM and BioNTech Stage Comebacks
What a comeback! Almonty's share price surged by more than 50% in August! There are good reasons for the rally. Tungsten is in short supply in the West and is urgently needed due to the ramp-up in weapons production in the US. In addition, Almonty has released convincing quarterly results and announced a share buyback program. Analysts have recently nearly doubled their price target. BioNTech's share price jump of over 25% is less attributable to the biotech company itself; the stock has benefited from the breakthrough achieved by rival Moderna. Meanwhile, long-term performer CTS EVENTIM also made a comeback last week. Does this mean the stock is returning to its long-term uptrend? Analysts recommend the share as a "Buy".
Read
Commented by Armin Schulz on August 12th, 2026 | 07:05 CEST
Three Paths to the Cancer Drug of the Future: BioNTech, Vidac Pharma, and Pfizer Under the Oncology Spotlight
Oncology has become the most dynamic field of innovation in the pharmaceutical industry. The focus is not on finding a miracle cure, but rather on developing highly precise, personalized therapies that target tumors at the molecular level. For investors, this market, which is growing at double-digit rates, is attractive in the long term. While there is a world of difference between established corporations and agile biotech companies with groundbreaking technology platforms, both offer enormous potential for value appreciation. Today, we take a look at three companies that are aiming to discover the next blockbuster drug: BioNTech, Vidac Pharma and Pfizer.
Read
Commented by Matthias Schomber on August 6th, 2026 | 07:30 CEST
Billions Lost at BioNTech, TeamViewer Hopes for a Turnaround, and Lahontan Gold Poised for a Breakout?
Welcome to today's market update, featuring three companies at very different stages of their development. On one side is Mainz-based flagship company BioNTech, which, following the COVID-19 boom, is now grappling with a sharp decline in earnings and the painful departure of its prominent founders. Meanwhile, software developer TeamViewer is working to regain investor confidence through a comprehensive strategic transformation that is beginning to show early signs of progress. At the same time, while uncertainty continues to surround these well-known technology and healthcare companies, a much smaller resource company may be on the verge of a significant move. Lahontan Gold has reported highly encouraging drilling results and could soon be approaching a technical breakout. Let's take a closer look at these three companies to identify where the most compelling investment opportunities may lie. Read on for the full analysis.
Read
Commented by Stefan Bode on July 24th, 2026 | 08:40 CEST
Opportunities & Risks in Q2 Earnings: Almonty Industries, BioNTech, Danaher, Pfizer, and Sartorius
Global equity markets remain highly dynamic, and the fundamental backdrop has changed rapidly in recent quarters. In today's report, we examine three compelling investment stories at critical turning points. We take a closer look at former pandemic-era pharmaceutical high-flyers that must now navigate new tariffs as they shift their focus toward cancer therapies. We also analyze a geopolitically indispensable producer of a critical raw material that is benefiting significantly from efforts to secure Western supply chains. Finally, we turn to the bioprocessing sector, where upcoming quarterly earnings could determine the industry's direction following recent market turbulence. Find out where the most attractive opportunities, and the key risks, may lie.
Read
Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST
Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight
Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.
Read
Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST
AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!
Created and published on behalf of Antimony Resources Corp.
The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.
Read
Commented by Matthias Schomber on July 6th, 2026 | 07:00 CEST
Burry's Short Attack on Micron Technology, BioNTech's Radical Overhaul and Strategic Resources: a Still-Quiet Commodities Player!
While the AI boom continues to promise enormous profits, the first cracks are beginning to appear. High-profile investors are suddenly betting against some of Wall Street's former—and in some cases already fallen—favourites. Will Micron Technology stage a successful turnaround, or is a deeper correction still ahead? At the same time, Germany's biotech sector is undergoing a period of profound change. Cost-cutting programs worth billions of euros and sweeping strategic realignments are putting investors' conviction to the test. Away from the spotlight, a potentially transformative story is also unfolding in the commodities sector. Investors seeking early exposure to the long-term trend in industrial decarbonization may want to take a closer look at Strategic Resources. We examine three companies from three very different industries—each offering a distinct investment opportunity.
Read
Commented by Fabian Lorenz on June 24th, 2026 | 08:40 CEST
Alarm at BMW! Sell-off at BioNTech! Desert Gold Undervalued!
Alarm at BMW. First, the company shocked shareholders with a profit warning. Now, business in China has collapsed. Analysts are finally reacting by slashing their estimates and price targets. Is it time to buy now? From the perspective of GBC Research, Desert Gold is the stock to buy right now. The company is set to transition from an explorer to a gold producer this summer. Analysts see its intrinsic value well above current price levels. And what about BioNTech? The share has been trading sideways for months. The announcement of location closures has drawn heavy criticism. Shareholders are equally disillusioned. Could rival Moderna, of all companies, now bring hope to the workforce?
Read
Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST
Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech
On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.
Read